Adcock shareholders postpone CFR buyout vote; FDA says common ADHD drugs can trigger painful erections;

@FiercePharma: Best-read this morning: GSK scraps doc payments, sales rep quotas in global marketing revamp. More | Follow @FiercePharma

@EricPFierce: FDA, EMA to share "information on inspections of bioequivalence studies" on generics. News | Follow @EricPFierce

@CarlyHFierce: A U.S. competitor to AstraZeneca's Nexium is here. Release | Follow @CarlyHFierce

> Shareholders of South Africa's Adcock Ingram agreed to postpone their vote on a new buyout offer from Chilean drugmaker CFR Pharmaceuticals until next month. Report

> The FDA and the European Medicines Agency (EMA) said they would work together to inspect facilities and data used to support applications for generic-drug approvals. Report

> After a favorable patent ruling, India's Lupin launched its generic version of the ViiV Healthcare HIV treatment Trizivir, with 180 days of marketing exclusivity under the Hatch-Waxman Act. Report

> The FDA's push for abuse-resistant opioid painkillers will disrupt the pain-relief market, Frost & Sullivan analysts said. Report

> ADHD drugs that, like Ritalin, contain the stimulant methylphenidate can caused prolonged, painful erections and even permanent damage to the penis, the FDA said; the median age of patients reporting the condition was 12.5 years. Report

> Alliance Pharma said it had acquired marketing rights in the U.K. and Ireland to Novartis' ($NVS) lip-moisturizing product Lypsyl. Report (sub. req.)

Medical Device News

@FierceMedDev: Medtronic kicks off another renal denervation trial as competitors lag behind. Story | Follow @FierceMedDev

@MarkHFierce: Find out how Dx developer Xagenix attracted a robust Series B despite the tough VC funding environment. Article from FierceDiagnostics | Follow @MarkHFierce

@MichaelGFierce: Artificial cells made en masse offer insight into delivery across membrane. News | Follow @MichaelGFierce

@GalenMoore: Medtronic plans a $6M expansion in Puerto Rico. Takeaway: I get to write about Puerto Rico after I shovel snow. More | Follow @GalenMoore

> Apollo Endosurgery raises $90M to help pay for Allergan's obesity intervention business. Article

> Stryker agrees to settle four metal hip lawsuits as hundreds more loom. Story

> Report: Man peddling a 'Star Trek'-style medical scanner will admit to fraud. Item

Biotech News

@FierceBiotech: After a Phase III flop, Acucela plots a $120M Japanese IPO. More | Follow @FierceBiotech

@JohnCFierce: Gilead races to the FDA with stellar PhIII results for breakthrough hep C combo. Story | Follow @JohnCFierce

@DamianFierce: Transcept: "Retrophin never presented any credible evidence of ability to finance purchase of our stock." Release | Follow @DamianFierce

@EmilyMFierce: Last issue of FierceBiotech Research until 2014: Newsletter. Until then, read us on the web: FierceBiotechResearch.com | Follow @EmilyMFierce

> Onconova tanks as its lead candidate flunks PhIII for pancreatic cancer. News

> Genentech's ex-R&D boss takes the reins at the Gates Foundation. Story

> Merck partners up with GlaxoSmithKline on its prize cancer immunotherapy. Article

Drug Delivery News

> Magnetic sperm-driven micro-robots swim to deliver drugs. More

> Artificial cells made en masse offer insight into delivery across membrane. Article

> Austrian team improves RNAi 'hairpin' structures for more efficient delivery. Story

> 'Walking' DNA motor on nanotube tracks could someday deliver drugs. Piece

> Belgian Cardio3 BioSciences corrals $5.5M for stem cell delivery tech trial. News

> Alnylam begins PhII trial for amyloidosis RNAi treatment. Item

Diagnostics News

> FDA warning: Avoid using test vs. mammography as cancer Dx screening tool. News

> Cynvenio, CollabRx will use data to personalize the cancer Dx process. More

> In tough funding times, Xagenic's detailed Dx work drew plenty of VC. Piece

> Natera finds Hong Kong berth for prenatal screening test. Story

> Navidea wants the FDA to approve a wider use of its injectable cancer imaging agent. Article

> Sundance Diagnostics is linking with Max Planck Institute on a suicide-risk blood test. More

> University of Cambridge finds one test now possible for most blood cancers. Item

And Finally... A woman in China died from a new strain of bird flu, the H10N8 virus. Report

Suggested Articles

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan

Pfizer struck a deal to produce Gilead Sciences' remdesivir, which has been running short at some hard-hit U.S. hospitals.